News

Nearly 1 in 8 people diagnosed with Parkinson’s disease in Finland within the past couple of decades were later given a different diagnosis, usually within two years, underscoring the need for better clinical criteria and regular checkups. When Parkinson’s and dementia with Lewy bodies, a neurodegenerative disease also…

Scientists have developed a blood test to detect Parkinson’s disease in its very early stages, before a person experiences the first symptoms that would normally prompt a Parkinson’s diagnosis, a study showed. After identifying that people with Parkinson’s have alterations in two types of transfer RNA fragments (tRFs),…

The Van Andel Institute (VAI) — founded nearly three decades ago to advance biomedical research and science education — is awarding its 2025 Jay Van Andel Award to a University of Pittsburgh professor for his work on environmental factors in Parkinson’s disease. This year’s award will be presented…

Suppressing the immune system to reduce brain inflammation, a known contributor to Parkinson’s disease progression, may offer a promising new strategy for slowing the disease, early trial results suggest. Specifically, azathioprine, a commonly used drug that suppresses immune activity, reduced motor symptoms and improved cognitive function in people…

The investigational liquid therapy ND0612 — an around-the-clock supply of levodopa/carbidopa infused via a pump under the skin — provides more stable motor control in people with Parkinson’s disease who experience motor fluctuations than standard immediate-release levodopa/carbidopa. That’s according to data from the randomized portion of the…

Crexont, an extended-release oral formulation of carbidopa and levodopa,  significantly improved sleep quality in people with Parkinson’s disease. That’s according to data based on additional analysis of the Phase 3 RISE-PD trial (NCT03670953). The results were detailed in a presentation, “Conversion to CREXONT in…

ION859, an injectable treatment being developed by Ionis Pharmaceuticals, was generally safe and well tolerated, and it reduced the levels of LRRK2 — a protein often overactive in Parkinson’s disease — even in patients without mutations in the gene that encodes it. These are data from a now-completed…

Serina Therapeutics will use $5 million in new funding to further develop SER-252 (POZ-apomorphine) as a treatment for advanced Parkinson’s disease, with a Phase 1 clinical study now expected by the end of the year. The company secured the financing from shareholders to support clinical testing of SER-252,…

Treatment for up to three years with Onapgo (apomorphine hydrochloride) — approved in the U.S. earlier this year as an add-on therapy for advanced Parkinson’s disease — significantly and sustainably reduced off time, when symptoms are not fully controlled, in adults with the neurodegenerative condition. Importantly, the researchers…

Although physical exercise has well-established benefits for people with Parkinson’s disease, too much of it may worsen fatigue and motor symptoms, according to a report of two cases in the U.K. Both patients believed that intense exercise could help them overcome the disease, including reversing the degeneration of dopaminergic…